Navigation Links
Bluemetal Architects appoints David Le Penske as Vice President of Health & Life Sciences
Date:1/30/2013

WATERTOWN, Mass., Jan. 30, 2013 /PRNewswire-iReach/ -- BlueMetal Architects, a leading design and technology services firm, today announced that it has appointed former Microsoft Health Solutions Group Director and Health IT entrepreneur, David Le Penske , to be Vice President of Health & Life Sciences.  Mr. Le Penske will be based in BlueMetal's Boston office and will be responsible for leading the Health and Life Sciences growth strategy for the company across BlueMetal's Boston, New York and Chicago locations.

Mr. Le Penske has a long track record of entrepreneurial and corporate leadership experience across sales, marketing, and development of strategic partnership alliances, including the last 10 years specifically in the Health IT industry. Most recently, he served as Vice President of Business Development and Sales for Get Real Health, a leading Maryland-based consumer health software company.  Prior to that, Mr. Le Penske served as Director, Microsoft Health Solutions Group where he was responsible for leading Microsoft's enterprise Amalga and consumer HealthVault sales and business development initiatives across Canada's government, business and consumer markets – including the MyHealth Alberta citizen portal project. Mr. Le Penske also managed the strategic partner relationship with TELUS concerning TELUS health space, powered by Microsoft HealthVault.

In 2003, Mr. Le Penske founded AccelMD, a leading supplier of healthcare information and navigation services and wellness solutions, to improve health and enhance the quality of life for individuals, g
'/>"/>

SOURCE BlueMetal Architects
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology news :

1. 3-V Biosciences Appoints Douglas I. Buckley, PhD, as Vice President of Biology
2. Conatus Pharmaceuticals Appoints Mark F. Morris as Head of Biostatistics
3. AnaptysBio Adds Dr. David L. Lacey and Dr. Michael Gallatin to Therapeutic Advisory Board
4. The American Society for Microbiology honors David Tobin
5. Environmental activist David Suzuki is fifth recipient of CWRU’s Inamori Ethics Prize
6. President, CEO Leppävuori, VTT: Finland should create a national bioeconomy strategy
7. UCLAs Yi Tang receives Presidential Green Chemistry Challenge Award from EPA
8. NASA Goddard scientist receives Presidential Early Career Award
9. ONR-funded young innovators recognized by President
10. President Obama honors MU researcher with National Medal of Science
11. Tortoise and the hare: New drug stops rushing cancer cells, slow and steady healthy cells unharmed
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/11/2014)... Minn. , Dec. 10, 2014  Data ... physiologic monitoring, has released a new series of ... of preclinical toxicology researchers. M series, part of ... toxicologists collect the best possible physiologic data when ... Adding functional endpoints to toxicology studies has ...
(Date:12/10/2014)... , Dec. 08, 2014 Research and Markets ... addition of the "Biometrics Market in Japan ... http://photos.prnewswire.com/prnh/20130307/600769 The ... such as rural banking and upgradation of the ... witnessed in the market. Besides the aforementioned projects, ...
(Date:12/3/2014)... Dec. 2, 2014   Marvin Test Solutions ... test solutions for military, aerospace, and manufacturing organizations, ... its successful TS-900 PXI semiconductor test platform ... of high-end systems to customers at a fraction ... to traditional ATE. "Our semiconductor ...
Breaking Biology News(10 mins):New telemetry implants expected to change how large animal toxicology studies are conducted 2Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3
... mothers-to-be have a remarkable way to protect their unborn ... can cause miscarriage and reactivate the ovulatory cycle, pregnant ... blocking their smell. Researchers from the European Molecular Biology ... nature of this ability. A surge of the chemical ...
... Biology (ASBMB) has announced the recipients of its ... for their outstanding achievements and contributions to science. ... Experimental Biology 2009 Meeting, April 18-22, in New ... NIDDK, National Institutes of Health, will give the ...
... Neurological experts from across the U.S. and other ... Medical Center will discuss the latest findings in basic ... International Fragile X Conference, to be held July 23-27 ... diagnosed with Fragile X also will be attending the ...
Cached Biology News:Pregnant mice block out unwelcome admirers to protect their pups 2ASBMB taps 8 scientists for top awards 2ASBMB taps 8 scientists for top awards 3Researcher helping to pioneer medical therapy for Fragile X Syndrome presents latest findings 2
(Date:12/17/2014)... (PRWEB) December 17, 2014 Xeno ... Excellence following its most recent COLA inspection. Xeno ... COLA, a national healthcare accreditation organization. Accreditation is ... of quality in day-to-day operations, demonstrate continued accuracy ... a rigorous on-site laboratory survey. , ...
(Date:12/17/2014)... , Dec. 16, 2014  Vermillion, Inc. (NASDAQ: ... on gynecologic disease, today announced the next step in ... premier bio-analytics solutions provider with the naming of current ... and Chief Executive Officer, while current Chairman of the ... to serve as Chairman. These changes are effective January ...
(Date:12/17/2014)... SAN FRANCISCO, Calif. , Dec. 17, 2014 ... results of a Phase 2 study evaluating the ... the treatment of patients with severe, chronic itch ... current standard of care, including topical steroids and ... was percent change in Visual Analog Scale (VAS) ...
(Date:12/15/2014)... & PETACH TIKVAH, Israel ... (NASDAQ: BCLI ), a leading developer of ... that wholly-owned subsidiary Brainstorm Cell Therapeutics Ltd. was awarded ... Israel,s Office of the Chief Scientist (OCS).  ... in receipt of grant support from the Office of ...
Breaking Biology Technology:Xeno Diagnostics Receives 3rd Award for Laboratory Excellence 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 4Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 2BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 3
... DNA2.0, the leading synthetic genomics company, announced today a significant ... interface, a customer-friendly site navigation, a database of published synthetic ... with a powerful resource for analyzing DNA and protein sequences. ... ...
... at the Canadian,Diabetes Association Congress, physicians will get ... phase 3b clinical study (LEAD(TM) 6) comparing,the investigational ... liraglutide, a human GLP-1 analog administered once daily ... (as,measured by HbA1c) than exenatide, a GLP-1 mimetic ...
... field called transformation optics may usher in a host ... ultra-powerful microscopes and computers by harnessing nanotechnology and "metamaterials." ... those in Einstein,s theory of general relativity, will be ... 17) in the journal Science . The article ...
Cached Biology Technology:DNA2.0 Launches New Website: Enhanced Design and Free Bioinformatics Tools Demonstrate DNA2.0's Customer Focus 2New Data From Head-to-Head Phase 3 Trial Demonstrate That Liraglutide is More Effective Than Exenatide in Treatment of Type 2 Diabetes 2New Data From Head-to-Head Phase 3 Trial Demonstrate That Liraglutide is More Effective Than Exenatide in Treatment of Type 2 Diabetes 3New Data From Head-to-Head Phase 3 Trial Demonstrate That Liraglutide is More Effective Than Exenatide in Treatment of Type 2 Diabetes 4New research field promises radical advances in optical technologies 2New research field promises radical advances in optical technologies 3New research field promises radical advances in optical technologies 4